Thursday New StockGoodie Profile $OREX
OREX - Orexigen Therapeutics Inc.
Company Overview
Website: http://www.orexigen.com/
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release). Orexigen is undertaking a range of commercialization activities, both on their own and with key strategic partners, to bring Contrave / Mysimba to patients around the world.
Orexigen believes strongly in the value provided by the ongoing innovation of the biopharmaceutical industry - for patients, for the physicians who treat them, for their caregivers, as well as for the broader healthcare system. Through advancements in the science of healthcare by biopharmaceutical companies, patients are receiving an increasing number of new, effective, reliable, and safe treatment options for a multitude of diseases. For patients, these medical advances represent better treatment options to manage their disease, with the potential to improve their daily lives and the ability to reduce the costs associated with their healthcare.
From 2000 to 2013, more than 450 new medicines were approved by the FDA. Investment in medical innovation continues to grow rapidly. New products generated through pharmaceutical R&D have contributed meaningfully to advancements in medicine, including:
83% reduction in the U.S. HIV/AIDS death rate
20% reduction in U.S. cancer death rates from their peak
94% cure rate for Hepatitis C
About Obesity
Obesity is a serious and rising health epidemic and has recently been declared a disease by the American Medical Association. It is a condition associated with having an excess of body fat, defined by genetic and environmental factors that are difficult to control when dieting. Obesity is classified as having a Body Mass Index (BMI) of 30 or greater.
It is estimated that nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions.
Products
Contrave
CONTRAVE is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.
Mysimba™
About Mysimba
Mysimba is a centrally acting anti-obesity product composed of a fixed dose combination of the active substances naltrexone and bupropion. Naltrexone is a mu-opioid antagonist and bupropion is a norepinephrine and dopamine reuptake inhibitor. Both compounds affect key circuitry in two areas of the brain. The first is the arcuate nucleus of the hypothalamus, an area of the brain that plays a critical role in the control of food intake and energy expenditure. The second is the mesolimbic dopaminergic reward system, a region of the brain that is important for processing the rewarding aspects of food and food related stimuli. Both bupropion and naltrexone act in the mesolimbic reward system to influence eating behavior.
Orexigen's Mysimba™ Approved in Europe for the Treatment of Obesity
SAN DIEGO, March 26, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the European Commission has granted marketing authorization for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (=18 years) with an initial Body Mass Index (BMI) of = 30 kg/m2 (obese), or = 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.
"The granting of European marketing authorization for Mysimba is a significant milestone for Orexigen. European approval is an important step in our pursuit to bring new treatment options to the many patients who struggle with obesity in Europe and around the world," said Mike Narachi, CEO of Orexigen.
In the United States, the drug was approved in September 2014 and is marketed under a separate brand name. Further information can be found at http://www.orexigen.com/.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc., San Diego, California, developed Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) for weight management. Orexigen owns all rights to Mysimba outside of North America, and the Company's strategy is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization.
Financials & Filings
http://finance.yahoo.com/q/pr?s=OREX+Profile
News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire (Wed, May 4)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire (Tue, May 3)
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development
PR Newswire (Mon, May 2)
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients
PR Newswire (Mon, Apr 25)
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees
Contact
Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla, CA 92037
Phone: (858) 875-8600
Fax: (858) 875-8650
Goodies Newsletter Sign Up http://www.stockgoodies.com
WANT A QUICKER WAY TO GET OUR ALERTS?
TEXT "Stock" to 31279
Follow Us on Twitter
http://twitter.com/StockGoodies
Follow Us on Facebook
http://www.facebook.com/groups/STOCKGOODIES
Follow Us on PennyStockTweets
http://www.pennystocktweets.com/profile/StockGoodies
Contact Us admin@stockgoodies.com
Compensation:
http://stockgoodies.com/disclaimer.html
OREX - Orexigen Therapeutics Inc.
Company Overview
Website: http://www.orexigen.com/
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release). Orexigen is undertaking a range of commercialization activities, both on their own and with key strategic partners, to bring Contrave / Mysimba to patients around the world.
Orexigen believes strongly in the value provided by the ongoing innovation of the biopharmaceutical industry - for patients, for the physicians who treat them, for their caregivers, as well as for the broader healthcare system. Through advancements in the science of healthcare by biopharmaceutical companies, patients are receiving an increasing number of new, effective, reliable, and safe treatment options for a multitude of diseases. For patients, these medical advances represent better treatment options to manage their disease, with the potential to improve their daily lives and the ability to reduce the costs associated with their healthcare.
From 2000 to 2013, more than 450 new medicines were approved by the FDA. Investment in medical innovation continues to grow rapidly. New products generated through pharmaceutical R&D have contributed meaningfully to advancements in medicine, including:
83% reduction in the U.S. HIV/AIDS death rate
20% reduction in U.S. cancer death rates from their peak
94% cure rate for Hepatitis C
About Obesity
Obesity is a serious and rising health epidemic and has recently been declared a disease by the American Medical Association. It is a condition associated with having an excess of body fat, defined by genetic and environmental factors that are difficult to control when dieting. Obesity is classified as having a Body Mass Index (BMI) of 30 or greater.
It is estimated that nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions.
Products
Contrave
CONTRAVE is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.
Mysimba™
About Mysimba
Mysimba is a centrally acting anti-obesity product composed of a fixed dose combination of the active substances naltrexone and bupropion. Naltrexone is a mu-opioid antagonist and bupropion is a norepinephrine and dopamine reuptake inhibitor. Both compounds affect key circuitry in two areas of the brain. The first is the arcuate nucleus of the hypothalamus, an area of the brain that plays a critical role in the control of food intake and energy expenditure. The second is the mesolimbic dopaminergic reward system, a region of the brain that is important for processing the rewarding aspects of food and food related stimuli. Both bupropion and naltrexone act in the mesolimbic reward system to influence eating behavior.
Orexigen's Mysimba™ Approved in Europe for the Treatment of Obesity
SAN DIEGO, March 26, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the European Commission has granted marketing authorization for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (=18 years) with an initial Body Mass Index (BMI) of = 30 kg/m2 (obese), or = 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.
"The granting of European marketing authorization for Mysimba is a significant milestone for Orexigen. European approval is an important step in our pursuit to bring new treatment options to the many patients who struggle with obesity in Europe and around the world," said Mike Narachi, CEO of Orexigen.
In the United States, the drug was approved in September 2014 and is marketed under a separate brand name. Further information can be found at http://www.orexigen.com/.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc., San Diego, California, developed Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) for weight management. Orexigen owns all rights to Mysimba outside of North America, and the Company's strategy is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization.
Financials & Filings
http://finance.yahoo.com/q/pr?s=OREX+Profile
News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire (Wed, May 4)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire (Tue, May 3)
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development
PR Newswire (Mon, May 2)
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients
PR Newswire (Mon, Apr 25)
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees
Contact
Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla, CA 92037
Phone: (858) 875-8600
Fax: (858) 875-8650
Goodies Newsletter Sign Up http://www.stockgoodies.com
WANT A QUICKER WAY TO GET OUR ALERTS?
TEXT "Stock" to 31279
Follow Us on Twitter
http://twitter.com/StockGoodies
Follow Us on Facebook
http://www.facebook.com/groups/STOCKGOODIES
Follow Us on PennyStockTweets
http://www.pennystocktweets.com/profile/StockGoodies
Contact Us admin@stockgoodies.com
Compensation:
http://stockgoodies.com/disclaimer.html
